alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

Trial Details

NCT ID
NCT03692429
Phase
PHASE1
Sponsor
Celyad Oncology SA
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • CYAD-101
  • FOLFOX
  • FOLFIRI
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843
  • Brussels, Belgium|50.85045,4.34878
  • Edegem, Belgium|51.15662,4.44504
  • Leuven, Belgium|50.87959,4.70093

Key Eligibility Criteria

  • Histologically proven metastatic adenocarcinoma of the colon or rectum.
  • Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum.
  • Recurrent/progressing disease after at least one line of systemic therapy for metastatic disease.
  • Unequivocal and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →